Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review

Clinical Therapeutics

Volumn 33, Issue 10, 2011, Pages 1413-1432

  Sarnes, Evelyn ^a   Crofford, Leslie ^b   Watson, Maria ^c   Dennis, Greg ^c   Kan, Hong ^c   Bass, Damon ^c  

^a XCENDA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Adverse events; Corticosteroids; Cost analysis; Long term treatment

Indexed keywords

BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUOCORTOLONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE;

ACUTE HEART INFARCTION; ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ADVERSE OUTCOME; ANKLE EDEMA; ANXIETY; ARTICLE; ASEPTIC NECROSIS; ASTHMA; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BLADDER CANCER; BLOOD PRESSURE; BONE NECROSIS; CAROTID ATHEROSCLEROSIS; CATARACT; CHICKENPOX; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; CROHN DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; EARDRUM PERFORATION; ECCHYMOSIS; ELECTROLYTE BALANCE; ENDOCRINE SYSTEM; EPIGASTRIC PAIN; EPISTAXIS; EUPHORIA; EYE DISEASE; FEMUR FRACTURE; FIBROSING ALVEOLITIS; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; GLAUCOMA; GLUCONEOGENESIS; HAND TREMOR; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART MUSCLE FIBROSIS; HERPES ZOSTER; HIP FRACTURE; HIRSUTISM; HORMONE RELEASE; HOSPITAL INFECTION; HUMAN; HYPERACTIVITY; HYPERGLYCEMIA; HYPERPHAGIA; HYPERTENSION; HYPOKALEMIA; HYPOMANIA; INCIDENCE; INFECTION; INSOMNIA; IRRITABILITY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEG EDEMA; LIBIDO; LIMB FRACTURE; LIPODYSTROPHY; LISTLESSNESS; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MELANOMA; MENOPAUSAL SYNDROME; MENTAL DISEASE; MENTAL HEALTH; METABOLIC SYNDROME X; MOOD DISORDER; MOON FACE; MUSCLE CRAMP; MUSCLE WEAKNESS; MYCOSIS; MYELOMA; MYOPATHY; NERVE CELL NETWORK; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; OBESITY; OPTIC NEURITIS; OSTEOPOROSIS; OTORRHEA; PEPTIC ULCER; PERCEPTION DEAFNESS; PSYCHOSIS; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RIB FRACTURE; RISK REDUCTION; SEPSIS; SIDE EFFECT; SKIN BRUISING; SKIN DISEASE; SLEEP DISORDER; STOMACH ACID SECRETION; STOMACH DISCOMFORT; STOMACH DISEASE; STOMACH MUCOSA INJURY; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THRUSH; TUBERCULOSIS; ULCER; ULCER PERFORATION; UNITED STATES; VASCULAR DISEASE; VERTEBRA FRACTURE; VERTIGO; WEIGHT GAIN; WOUND HEALING IMPAIRMENT; WRIST FRACTURE;

ADRENAL CORTEX HORMONES; ADVERSE DRUG REACTION REPORTING SYSTEMS; COSTS AND COST ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; HUMANS; INCIDENCE; UNITED STATES;

EID: 80054947972     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.009     Document Type: Article

References (69)

1. Elixhauser A., Owens P. Adverse Drug Events in U.S. Hospitals, 2004 Agency for Healthcare Research and Quality, Accessed March 5, 2010. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb29.pdf.
2. Hoes J.N., Jacobs J.W., Verstappen S.M., et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009, 68:1833-1838.
3. Raofi S., Schappert S.M. Medication therapy in ambulatory medical care: United States, 2003-4. National Center for Health Statistics. Vital Health Stat 2006, 13:1-40.
4. Buttgereit F., Straub R.H., Wehling M., Burmester G.R. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004, 50:3408-3417.
5. Zonana-Nacach A., Barr S.G., Magder L.S., et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000, 43:1801-1808.
6. Karp I., Abrahamowicz M., Fortin P.R., et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?. Arthritis Rheum 2008, 59:169-175.
7. Manson S.C., Brown R.E., Cerulli A., Vidaurre C.F. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009, 103:975-994.
8. Pisu M., James N., Sampsel S., Saag K.G. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology 2005, 44:781-788.
9. Hailey D., Ohinmaa A., Roine R. Study quality and evidence of benefit in recent assessments of telemedicine. J Telemed Telecare 2004, 10:318-324.
10. Akerkar G.A., Peppercorn M.A., Hammel M.B., Parker R.A. Corticosteroid-associated complications in elderly Crohn's disease patients. Am J Gastroenterol 1997, 92:461-464.
11. Avina-Zubieta JA, Abrahamowicz M, Choi HK, et al. Corticosteroids increase risk for acute myocardial infarction in rheumatoid arthritis. The effects of careful modeling of cumulative exposure. Poster presented at: American College of Rheumatology 2009 Annual Meeting; October 17-21, 2009; Philadelphia, Pa.
12. Bolanos S.H., Khan D.A., Hanczyc M., et al. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol 2004, 92:500-505.
13. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972, 13(5 Part 1):694-698. Boston Collaborative Drug Surveillance Program.
14. Brown E.S., et al. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 2002, 22:55-61.
15. Christiansen C.F., Christensen S., Mehnert F., et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 2009, 169:1677-1683.
16. Chrousos G.A., Kattah J.C., Beck R.W., Cleary P.A. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 1993, 269:2110-2112.
17. Conn H.O., Poynard T. >Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994, 236:619-632.
18. Da Silva A.N., Schiff D. Adrenal insufficiency secondary to glucocorticoid withdrawal in patients with brain tumor. Surg Neurol 2007, 67:508-510.
19. de Vries F., Bracke M., Leufkens H.G.M., et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007, 56:208-214.
20. Dietrich K., Schned A., Fortuny J., et al. Glucocorticoid therapy and risk of bladder cancer. Br J Cancer 2009, 101:1316-1320.
21. Dowell S.F., Bresee J.S. Severe varicella associated with steroid use. Pediatrics 1993, 92:223-228.
22. Einaudi S., Bertorello N., Masera N., et al. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2008, 50:537-541.
23. Fardet L., Cabane J., Kettaneh A., et al. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology 2007, 46:1102-1106.
24. Fardet L., Flahault A., Kettaneh A., et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007, 157:142-148.
25. Gabriel S.E., Sunku J., Salvarani C., et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997, 40:1873-1878.
26. Garcia-Berrocal J.R., Ramirez-Camacho R., Lobo D., et al. Adverse effects of glucocorticoid therapy for inner ear disorders. ORL J Otorhinolaryngol Relat Spec 2008, 70:271-274.
27. Greenberg J.D., Kavanaugh A., Hochberg M., et al. Association of methotrexate (MTX), TNF-inhibitors (TNF-1) and prednisone (PRED) with risk of infection among RA patients. Ann Rheum Dis 2007, 66. 171-171.
28. Hafstrom I., Rohani M., Deneberg S., et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis-a randomized study. J Rheumatol 2007, 34:1810-1816.
29. Hernandez-Diaz S., Rodriguez L.A. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001, 153:1089-1093.
30. Huscher D., Thiele K., Gromnica-Ihle E., et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009, 68:1119-1124.
31. Jensen A.O., Thomsen H.F., Engebjerg M.C., et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009, 100:200-205.
32. Jick S.S., Lieberman E.S., Rahman M.U., Choi H.K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55:19-26.
33. Kameda H., Amano K., Nagasawa H., et al. Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases. Intern Med 2009, 48:1931-1938.
34. Luo J.C., Chang F.Y., Chen T.S., et al. Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy. Br J Clin Pharmacol 2009, 68:252-259.
35. Messer J., Reitman D., Sacks H.S., et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983, 309:21-24.
36. Naber D., Sand P., Heigl B. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996, 21:25-31.
37. Nerome Y., Imanaka H., Nonaka Y., et al. Frequent methylprednisone pulse therapy is a risk factor for steroid cataracts in children. Pediatr Int 2008, 50:541-545.
38. Ng A.C., Kumar S.K., Russell S.J., et al. Dexamethasone and the risk for adrenal suppression in multiple myeloma. Leukemia 2009, 23:1009-1011.
39. Nishimura K., Harigai M., Omori M., et al. Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology 2008, 33:395-403.
40. Panoulas V.F., Douglas K.M.J., Stavropoulos-Kalinoglou A., et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:72-75.
41. Patel H., Macarthur C., Johnson D. Recent corticosteroid use and the risk of complicated varicella in otherwise immunocompetent children. Arch Pediatr Adolesc Med 1996, 150:409-414.
42. Piper J.M., Ray W.A., Daugherty J.R., Griffin M.R. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991, 114:735-740.
43. Poele E.M., de Bont E.S.J.M., Boezen M., et al. Dexamethasone in the maintenance phase of acute lymphoblastic leukemia treatment: Is the risk of lethal infections too high?. Eur J Cancer 2007, 43:2532-2536.
44. Proven A., Gabriel S.E., Orces C., et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703-708.
45. Reyes M., Hernandez M., King A., et al. Corticosteroid-induced osteoporosis in children: outcome after two-year follow-up, risk factors, densitometric predictive cut-off values for vertebral fractures. Clin Exp Rheumatol 2007, 25:329-335.
46. Saag K.G., Koehnke R., Caldwell J.R., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994, 96:115-123.
47. Shibatani M., Fujioka M., Arai Y., et al. Degree of corticosteroid treatment within the first 2 months of renal transplantation has a strong influence on the incidence of osteonecrosis of the femoral Head. Acta Orthopaedica 2008, 79:631-636.
48. Smyllie H.C., Connolly C.K. Incidence of serious complications of corticosteroid therapy in respiratory disease. Thorax 1968, 23:571-581.
49. Sosa M., Jodar E., Saavedra P., et al. Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone. Eur J Intern Med 2008, 19:51-56.
50. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
51. Sugiyama T., Tatsuno I., Suzuki S., et al. Incidence of symptomatic vertebral fracture with high-dose glucocorticoid treatment in the Chiba-Shimoshizu rheumatic cohort between 1986 and 2006. Endocr J 2009, 56:591-599.
52. Toms T.E., Panoulas V.F., Douglas K.M.J., et al. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2008, 10:R145.
53. Uzu T., Harada T., Sakaguchi M., et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 2007, 105:c54-c57.
54. Varas-Lorenzo C., Rodriguez L.A.G., Maguire A., et al. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis 2007, 192:376-383.
55. Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 2008, 82:249-257.
56. Walsh L.J., Wong C.A., Oborne J., et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001, 56:279-284.
57. Schäcke H., Döcke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharm Therapeutics 2002, 96:23-43.
58. Schimmer B.P., Funder J.W. ACTH, adrenal steroids, and pharmacology of the adrenal cortex. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2011, McGraw-Hill, New York, NY. 12th ed. L.L. Brunton, B.A. Chabner, B.C. Knollmann (Eds.).
59. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 1996, 39:1791-1801. American College of Rheumatology.
60. Incidence and costs to Medicare of fractures among Medicare beneficiaries aged ≥65 years-United States, July 1991-July 1992. MMWR Morb Mort Weekly Rep 1996, 45:877-883.
61. Boudreau D.M., Malone D.C., Raebel M.A., et al. Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord 2009, 7:305-314.
62. Russell M.W., Huse D.M., Drowns S., et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998, 81:1110-1115.
63. Suyama J., Savitz L., Chang H., Allswede M. Financial implications of hospital response to bioterrorism based on diagnosis-related group analysis. Prehosp Disaster Med 2007, 22:145-148.
64. Patel M.S., Gebremariam A., Davis M.M. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect Control Hosp Epidemiol 2008, 29:1157-1163.
65. Zhou F., Harpaz R., Jumaan A.O., et al. Impact of varicella vaccination on health care utilization. JAMA 2005, 294:797-802.
66. Ozminkowski R.J., Wang S., Walsh J.K. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007, 30:263-273.
67. Luppa M., Heinrich S., Angermeyer M.C., et al. Cost-of-illness studies of depression: a systematic review. J Affect Disord 2007, 98:29-43.
68. Mauskopf J.A., Simon G.E., Kalsekar A., et al. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety 2009, 26:83-97.
69. Kleinman L., Lowin A., Flood E., et al. Costs of bipolar disorder. Pharmacoeconomics 2003, 21:601-622.